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Clinical, Molecular, and Genomic
Changes After Left Ventricular
Assist Device Implantation
We read with interest the state-of-the-art paper by Hall et al. (1)
that was recently published in the Journal. The paper summarizes
the main molecular and genomic changes in response to mechan-
ical unloading by left ventricular assist devices (LVADs). How-
ever, we consider that, as suggested by the title of the review, the
clinical changes induced by left ventricular (LV) unloading deserve
the same attention because to date, the decisions to remove
LVADs after detection of unloading-induced cardiac recovery
have all been ultimately based on clinical parameters (2–8).
Unfortunately, Hall et al. (1) provide neither data on clinical
parameters that can predict weaning success nor data on long-term
cardiac function and transplantation-free outcome after weaning
from LVADs, although such information already exists (2–7).
Since 1995, we have weaned 78 patients from LVADs, and
echocardiographic data obtained during “off-pump” trials were the
cornerstone of weaning decisions. We found that LVAD removal
is a feasible therapeutic option with potentially successful results
for 15 years even with incomplete unloading-promoted cardiac
recovery (LV ejection fraction: 45% to 50%) (7). In patients with
dilated cardiomyopathy (DCM) as the underlying cause for heart
failure (HF), the post-weaning 5-year freedom from HF recur-
rence reached 66% (7). Kaplan-Meier estimates of overall survival
after weaning revealed probabilities of 71.4  7.1% and 65.7 
7.6% for 5- and 10-year survival, respectively (7). We also showed
that parameters of pre-explantation cardiac function, LV size and
geometry, their stability during final “off-pump” trials, and HF
duration before LVAD implantation allow detection of patients
with the potential to remain stable for 5 post-weaning years
(4,6,7).
Data on beta-adrenergic signaling and calcium handling in
recovery patients presented by Hall et al. show that the assessment
of molecular and genomic changes in response to unloading byLVADs can indeed be potentially helpful for future improvement
of weaning protocols. The review discusses a study recently
published by Ogletree et al. (9), who found that the favorable
effects of unloading on calcium handling and contractility are time
dependent (highest during the first 4 months of unloading;
thereafter, with longer duration of LVAD support, there is a
reversal to failing levels). These observations concord with our
clinical observations in DCM patients weaned from LVADs.
Thus, the patients with long-term post-weaning cardiac stability
had required a significantly shorter time of mechanical unloading
(4.3  0.7 months) until maximal myocardial improvement was
reached than those with heart failure recurrence during the first 5
years after LVAD removal (6.9  1.7 months). Moreover, the
necessity of more than 6 months of unloading until recovery
appeared to be a risk factor for HF recurrence after weaning (4,6).
As mentioned by Hall et al. (1), reversal of the proinflammatory
state is also an important change induced by ventricular unloading.
However, the authors omit to mention the autoantibodies, espe-
cially the beta1-adrenoreceptor autoantibodies (AABs), which
appear particularly relevant from a pathophysiological point of
view in DCM patients (10). Before LVAD implantation, 97.1% of
our weaned DCM patients tested positive for beta1-AABs,
whereas after 3 to 31 weeks of LV unloading, the beta1-AABs
disappeared in 97% of those patients (6). At LVAD explantation,
only 3% of DCM patients with cardiac recovery remained positive
for beta1-AABs.
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Reply
We are writing to thank Drs. Hetzer, Dandel, and Knosalla for
responding to our state-of-the-art paper (1). As stated, we did not
provide detailed weaning success from left ventricular assist de-
vices. We recognize that your group has provided data in this area.
In addition, the molecular data regarding the beta1-adrenoreceptor
autoantibodies are a new direction for the field, and we regret that
we did not include these references in our paper.*Jennifer L. Hall, PhD
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